HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

DVA

DaVita Inc. (S&P 500)

Healthcare — Medical Care Facilities

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Buy 2.4 / 5 7 analysts
$176.35
+$1.43 (+0.82%)
Target: $219.86 (24.7%)

Price History

52-Week Range
Sign in to add DVA to a watchlist or set price alerts.

Fundamentals

Market Cap$11.25B
P/E Ratio (TTM)14.93
Forward P/E10.29
EPS (TTM)$11.81
Dividend Yield-
Profit Margin6.05%
Revenue Growth5.20%
ROE88.48%
Debt/Equity1241.99
Recommendation Buy 2.4
Analyst Target$219.86
Analysts7
Next Earnings Aug 4, 2026 AMC
Indexes S&P 500

Technical Indicators

RSI (14)44.2
Beta0.83
SMA 20$181.98
SMA 40$180.33
52-Week High$247.49
52-Week Low$101.00
50-Day Avg$191.69
200-Day Avg$169.51
Avg Volume799.4K
Volume653.5K

Performance Analysis

BULLISH

DVA shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 51% of its 52-week range.
~ RSI at 44.2 is in neutral territory.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
+ P/E of 14.9 suggests the stock may be undervalued.
~ Modest revenue growth of 5.2% year-over-year.
+ Wall Street consensus is "Buy" from 7 analysts.
+ Average analyst target of $219.86 implies 24.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Oct 01, 2026 21:00 UTC

Back to Screener Export Report